Heroes in Drug Discovery
This award celebrates scientists who have made significant contributions to human healthcare.
The RISE Fellows at Drew University have selected Amgen’s drug discovery program of LUMAKRAS (sotorasib) as recipients of Drew University’s “Heroes in Drug Discovery” award based on the discovery of the first FDA approved KRAS inhibitor for the treatment of cancer.Through the Heroes program, our objective is to celebrate individuals who have made significant contribution to healthcare, as well as connect them to the best and brightest science undergraduates whose passions, interests, and drive position them to be the next leaders in science research.This event is supported by a grant from Pfizer and administered by the Independent College Fund of NJ.
To register/RSVP for this event, please use the form below. If you have any questions, please email email@example.com.